Table 2. Overview of Studies on PDMS Compound Sorption^a.

study (main class of compounds studied)	compounds: totalb	TPSA < 0.9 nm2, H-Bd < 2b	recovery < 0.7b	solution	non-PDMS controlsc	plasma treatment	study typed	perfusione	duration t [h]f	liquid volume [μL]	surface area [cm2]	ratio R [mm–1]
present work (neural drugs)	13g	10	0	CCM or SFM	√	√	μF	↶	24	2500	1	0.04
present work (model Shirure & George)58	13g	10	7						24	2500	1	0.04
Auner et al.(11) (cytotoxins)	19	9	3	PBS			I		24+	2500	0.8	0.03
van Midwoud et al.(12) (liver metabolites)	9	4	0	SFM	√	√	μF	→	2	600	0.4	0.07
van Meer et al.(10) (cardiac drugs)	4	3	2	PBS	√		I		3	250	0.3	0.14
Domansky et al.(14) (varied)	6	4	4	PBS	√	?h	I		72	30	0.3	1.0
Lohasz et al.(13) (varied)	6	3	3	SFM	√	?h	μF	↶	10+	150	>10	>7
Wang et al.(9) (varied)	5	1	2	PBS		√	μF		4.5	15	1.7	11
Auner et al.(11) (cytotoxins)	13	5	3	PBS			μF		6+	<13	<0.9	12

^aThe table summarizes some of the relevant parameters of the studies. We excluded studies with quantitative results for less than three compounds. Values are estimated from available data where not explicitly stated in the relevant papers. R, surface area-to-liquid volume ratio.

^bNumber of compounds in total; meeting Auner et al.’s proposed criteria of TPSA < 0.9 nm² and H-Bd < 2;^11,56 and with PDMS sorption > 30%.

^cNon-PDMS controls are required to account for, for example, thermal degradation losses, and for inclusion in Figure 2b.

^dMicrofluidic (μF) or disk immersion (I)-type experiments.

^eRecirculating ↶ or linear →.

^fFor time-resolved studies which continued measuring beyond where steady-state conditions were achieved, we denote the typical duration to the steady state instead (+).

^gThough our study includes 18 compounds in total, sorption quantification in devices is only possible for 13 due to the compounding losses discussed in Section 3.2.

^hQuestion marks (?) denote works where plasma treatment was studied, but where it remains unclear whether it was applied for the sorption measurements.